DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Vanta Bioscience Ltd (VANTABIO) share price today?

Vanta Bioscience Ltd (VANTABIO) is trading at ₹25.29 on the BSE, up 0.00% on the day. Source: DocStoX.

What is the PE ratio of Vanta Bioscience Ltd?

Vanta Bioscience Ltd has a price-to-earnings (PE) ratio of 168.6 in the Healthcare sector.

What is the market capitalisation of Vanta Bioscience Ltd?

Vanta Bioscience Ltd has a market capitalisation of approximately ₹18 crore.

Vanta Bioscience Ltd

VANTABIO·BSE·Healthcare

₹25.29▲ +0.00 (+0.00%)

⚠️Trading suspended — last traded ₹25.29 on 13 Jul 2026 (8 days ago). Not a live price.

Healthcare · Healthcare Services

Carries meaningful debt — watch the balance sheet

52W₹15

₹3164%

Open

₹25.29

High

₹25.29

Low

₹25.29

Prev Close

₹25.29

Volume

750

VWAP

₹25.29

Snapshot

Key fundamentals

Market Cap

₹18 Cr

P/E Ratio

168.60Expensive

P/B Ratio

0.85

EPS

₹0.15

Book Value

₹29.77

ROE

0.70%Weak

ROCE

-11.58%Weak

Dividend Yield

0.00%

Debt / Equity

1.80High

Face Value

₹10.00

52W High

₹31.33

52W Low

₹14.71

Sector

Healthcare

Industry

Healthcare Services

Expensive

None moatHigh uncertainty

Fair value estimate

₹25

▼ 1.1%downside

Trading at ₹25 — 1% above our estimate

BearFair valueBull

₹21₹25₹29

/100

Business quality — Watch the fundamentals

Growth 50Profitability 50Efficiency 0Valuation 5

Plain English

Our view

Carries meaningful debt — watch the balance sheet
Promoters hold a controlling stake
High leverage — debt exceeds 1.5× equity

Strengths

Promoters hold a controlling stake

Risks

High leverage — debt exceeds 1.5× equity
Weak returns on equity (1%)
Expensive — trades at 169× earnings

How we got there

Fair value methods

Residual income

1% ROE fading to 14% over ~3 yrs, on ₹30 book

₹25

Relative P/E

Needs positive EPS

—

Graham floor

Needs positive EPS

—

Analyst target

No analyst coverage

—

Blended fair value₹25

What the numbers say

Investment thesis

Bull case

Promoters hold a controlling stake

Bear case

High leverage — debt exceeds 1.5× equity
Weak returns on equity (1%)
Expensive — trades at 169× earnings

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

168.6Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

0.7%Weak

Above 15% is considered healthy for Indian equities

ROCE

-11.6%Weak

Above 18% means capital is working hard

Debt/Eq

1.80High

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹18 Cr

P/B

0.85

EPS

₹0.15

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 168.6×

Growth

Shrinking

-32% rev CAGR

Profitability

Modest

0.7% ROE

Financial health

Leveraged

D/E 1.80

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹18,967 Cr

Trades1

VWAP₹25.29

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-32.2%

-28.6%

10Y

—

Profit

—

-53.3%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Stock is trading at 0.85 times its book value

Watch-outs

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -28.6% over past five years.
Company has a low return on equity of -15.6% over last 3 years.
Company might be capitalizing the interest cost
Company has high debtors of 513 days.
Working capital days have increased from -636 days to 435 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

72.8%0.00

Public

24.5%+0.85

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

2.7%

Total shareholders

426+7 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.81%

Public24.51%

Others2.68%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation. [1]